---
freshness:
  last-reviewed: 2025-01-28
  data-year: 2024
  review-cycle: 12
  sections:
    - name: "Legislation Evaluations"
      data-year: 2024
    - name: "Engagement Consistency Assessment"
      data-year: 2024
notes:
  - Revisit after DEA final rule on cannabis rescheduling
  - Update after any Congressional votes on scheduling reform legislation
  - Flag any new Supreme Court rulings on drug scheduling for reassessment
  - Update after elections to reflect any changed party positions
sources:
  count: 35
  verified: 2025-01-28
  broken: 0
---

# Drug Scheduling: Political Perspectives Analysis

## Overview

This document analyzes drug scheduling reform through nine distinct political perspectives, evaluating current state assessments, root cause analyses, proposed solutions, and legislation. Drug scheduling raises fundamental questions about the proper relationship between science and government power, the role of law enforcement in medical classification, the limits of federal authority over state policy, and whether criminal penalties for drug offenses should be determined by pharmacological evidence or political judgment.

Different political traditions offer distinct visions for how to approach these questions. This analysis examines the issue through nine perspectives, exploring how each tradition approaches the core questions of scheduling authority, research access, cannabis rescheduling, and criminal penalty reform.

## Perspective Definitions

| Perspective | Core Values | Policy Orientation |
|-------------|-------------|-------------------|
| Conservative | Tradition, limited government, individual responsibility | Incremental change, fiscal restraint, market solutions |
| Liberal | Progress, equality, social responsibility | Government as problem-solver, regulation, safety nets |
| Progressive | Systemic change, economic justice, structural reform | Transformative reform, wealth redistribution, worker power |
| Libertarian | Individual liberty, minimal state, free markets | Deregulation, privatization, voluntary association |
| Constitutionalist | Original intent, enumerated powers, federalism | Strict constitutional limits, states' rights |
| Populist | Anti-elite, pro-worker, economic nationalism | Trade protection, anti-monopoly, immigration restriction |
| Centrist | Pragmatism, compromise, incremental progress | Bipartisan solutions, evidence-based policy |
| Religious Right | Faith-based values, traditional morality | Social conservatism, religious liberty |
| Democratic Socialist | Worker ownership, public goods, democratic control | Public investment, labor rights, universal programs |

## Scoring Framework

### Position Scores (1-10)

| Score | Meaning |
|-------|---------|
| 10 | Full agreement with project analysis |
| 7-9 | Substantial to strong agreement |
| 5-6 | Mixed/moderate agreement |
| 3-4 | Substantial disagreement |
| 1-2 | Strong opposition |

### Engagement Consistency (1-5)

This metric assesses how reliably a perspective's stated positions align with its underlying principles, and how stable those positions are when concerns are addressed. Higher scores indicate more predictable negotiating partners.

| Level | Label | Indicators |
|-------|-------|------------|
| 5 | Highly Consistent | Stated positions reflect underlying principles; positions stable when concerns addressed |
| 4 | Mostly Consistent | Principles generally align with positions; minor strategic flexibility |
| 3 | Mixed Consistency | Some positions principled, others reflect coalition pressures or unstated concerns |
| 2 | Low Consistency | Positions shift frequently; stated concerns differ from underlying priorities |
| 1 | Unpredictable | Positions appear driven primarily by opposition dynamics rather than principles |

**Coalition-Building Considerations:**

- Alignment gap: When stated concerns differ from underlying priorities, addressing stated concerns may not secure support
- Position stability: Perspectives with shifting positions require ongoing negotiation
- Principle consistency: Perspectives that apply principles uniformly are more predictable partners
- Internal diversity: Some perspectives contain factions with different priorities

### Legislation Status Reference (as of January 2025)

| Bill/Amendment | Type | Current Status | Last Action |
|----------------|------|----------------|-------------|
| *Cannabis rescheduling to Schedule III* | *Administrative (DEA)* | *Proposed rule published* | *NPRM May 2024; public comment and ALJ hearing* |
| *Evidence-Based Drug Classification Act* | *Federal* | *Proposed (not yet introduced)* | *Concept stage* |
| *SAFE Research Act* | *Federal* | *Proposed (not yet introduced)* | *Concept stage; similar bills have been introduced in prior Congresses* |
| *MORE Act* | *Federal* | *Passed House (117th, 118th); not enacted* | *House passage Dec 2020, Apr 2022* |
| *SAFE Banking Act* | *Federal* | *Passed House multiple times; stalled in Senate* | *Senate Committee approval 2023* |

*Note: Status reflects 118th-119th Congress. See [11-legislation.md](11-legislation.md) for full bill text.*

---

## Perspective Analyses

### Conservative Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | States concern about public safety and family values, but opposition is also driven by law enforcement constituency relationships and "soft on crime" political risks |
| Principle consistency | Inconsistent: supports federalism and limited government in most contexts but opposes applying these principles to drug scheduling reform |
| Goalpost stability | Moderate: has shifted from blanket opposition to accepting some cannabis reform (medical, veterans, hemp) while resisting broader scheduling changes |
| Zero-sum behavior | Some: tends to view scheduling reform as a concession to the political left rather than evaluating on merits |

**Justification:** Conservatives have shown meaningful evolution on drug policy -- supporting the First Step Act (2018), veterans' cannabis access, and some research access reforms. However, the gap between federalist principles (which would support state cannabis programs) and actual opposition to federal scheduling reform reveals that political dynamics and law enforcement constituency pressures drive positions as much as ideology.

**Evidence for assessment:**

- First Step Act (2018): Bipartisan sentencing reform supported by President Trump and many Congressional Republicans
- Hemp descheduling (2018 Farm Bill): Broad Republican support for removing hemp from Schedule I
- Cannabis rescheduling: Republican leadership has been divided, with some supporting (e.g., Rep. Dave Joyce, Sen. Rand Paul) and many opposing

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 5/10 | Accepts that scheduling system has flaws but resists framing DEA as incompetent or politically motivated; skeptical of characterizing cannabis as having established medical use |
| Root Cause Agreement | 4/10 | Disagrees that law enforcement control is the primary problem; attributes delays to legitimate caution; rejects racial motivation framing of drug war origins |

**Source references:**

- Heritage Foundation. "The Risks of Marijuana Legalization." Policy Brief, 2023.
- National Review editorial board positions on cannabis policy (varies; some columnists support reform)

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Independent Drug Classification Commission | 3/10 | Opposes removing authority from DEA; concerned about activist commission | Loss of law enforcement input; potential for permissive scheduling |
| Cannabis rescheduling to Schedule III | 5/10 | Increasingly supportive for medical purposes; cautious about recreational implications | Concerned about messaging; worried about youth use |
| Eliminate Schedule I research barriers | 7/10 | Broadly supportive of expanding research access | Want to maintain DEA oversight role |
| Cannabis descheduling | 2/10 | Opposes full descheduling; prefers states' rights approach without federal action | Fears federal legalization normalizes drug use |
| Evidence-based penalty reform | 4/10 | Supports some sentencing reform (as in First Step Act) but opposes elimination of mandatory minimums | Concerned about weakening deterrence and law enforcement tools |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| Evidence-Based Drug Classification Act | 3/10 | Opposes transfer of authority to independent commission; supports maintaining DEA role | Fear of "activist" commission; loss of enforcement linkage |
| SAFE Research Act | 6/10 | Generally supportive of research access reforms | Prefers DEA to retain oversight role; concerns about diversion |
| MORE Act (descheduling) | 2/10 | Opposes federal descheduling | Normalizing drug use; insufficient safety guardrails |

#### Alternative Proposals

Conservatives would prefer: (1) administrative rescheduling of cannabis to Schedule III through the existing DEA process (without structural reform); (2) maintaining DEA scheduling authority with enhanced HHS advisory input; (3) expanded research access through DEA administrative improvements rather than legislation; (4) STATES Act approach that protects state cannabis programs without federal descheduling or rescheduling.

#### Coalition Potential

- **Natural allies:** Religious Right (shared concerns about drug normalization); Populist (shared concerns about enforcement)
- **Potential bridges:** Centrist (common ground on incremental reform, research access); Libertarian (shared federalism concerns)
- **Unlikely partners:** Progressive, Democratic Socialist (fundamental disagreement on structural reform and penalty elimination)

---

### Liberal Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Positions on scheduling reform are generally consistent with stated principles of evidence-based policy, racial equity, and health-centered approaches |
| Principle consistency | High: applies pro-regulation, pro-science values consistently to scheduling reform; may sometimes prioritize political feasibility over comprehensive reform |
| Goalpost stability | Stable: has consistently supported cannabis rescheduling or descheduling, research access expansion, and penalty reform |
| Zero-sum behavior | Low: generally willing to negotiate incremental reforms while maintaining long-term goals |

**Justification:** Liberals have been consistent advocates for evidence-based scheduling reform, driven by genuine commitments to science, racial equity, and public health. The slight reduction from a 5 reflects occasional prioritization of political strategy over principle -- for example, some liberal legislators have supported rescheduling (Schedule III) as a compromise when descheduling would be more consistent with their stated positions.

**Evidence for assessment:**

- Democratic Party platform has supported cannabis rescheduling since 2016 and descheduling since 2020
- Biden administration initiated cannabis rescheduling process (2022-present)
- House Democrats passed the MORE Act (descheduling) in 2020 and 2022

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | Largely agrees with analysis of scheduling system's failures; would emphasize racial disparities even more |
| Root Cause Agreement | 8/10 | Agrees that DEA law enforcement authority and political dynamics drive scheduling dysfunction; accepts racial dimensions of drug war history |

**Source references:**

- Center for American Progress. "The Case for Cannabis Descheduling." 2023.
- Democratic Party Platform, 2024.
- Biden administration cannabis scheduling directives (October 2022)

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Independent Drug Classification Commission | 8/10 | Strongly supports independent scientific body; would prefer binding authority | Wants to ensure commission addresses equity concerns, not just scientific classification |
| Cannabis rescheduling to Schedule III | 7/10 | Supports as important step; prefers descheduling as ultimate goal | Rescheduling alone does not resolve banking, state program protection, or expungement |
| Eliminate Schedule I research barriers | 9/10 | Strongly supports research access expansion | No significant concerns; this is consensus position |
| Cannabis descheduling | 9/10 | Strongly supports; would pair with regulatory framework and equity provisions | Wants comprehensive reform including expungement and social equity licensing |
| Evidence-based penalty reform | 8/10 | Strongly supports penalty reform; would go further than proposed | Would prefer eliminating mandatory minimums for all drug offenses, not just possession |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| Evidence-Based Drug Classification Act | 8/10 | Supports commission structure; would strengthen equity provisions | Wants commission mandate to consider racial equity in scheduling decisions |
| SAFE Research Act | 9/10 | Strongly supports | No major objections |
| MORE Act (descheduling) | 9/10 | Core legislative priority; passed by House Democrats twice | Would add stronger equity provisions |

#### Alternative Proposals

Liberals support the analysis's proposals and would add: (1) mandatory racial equity impact assessments for all scheduling decisions; (2) cannabis social equity licensing provisions in any federal framework; (3) automatic expungement paired with rescheduling or descheduling; (4) federal regulation of cannabis advertising similar to tobacco.

#### Coalition Potential

- **Natural allies:** Progressive, Democratic Socialist (shared equity and public health priorities)
- **Potential bridges:** Centrist (common ground on evidence-based incremental reform); Libertarian (shared support for rescheduling/descheduling)
- **Unlikely partners:** Religious Right (fundamental disagreement on moral framing of drug use)

---

### Progressive Perspective

#### Engagement Consistency Assessment

**Score: 5/5 - Highly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Positions on scheduling reform are deeply consistent with systemic justice, anti-carceral, and corporate accountability principles |
| Principle consistency | Very high: applies structural reform lens uniformly; supports most ambitious reforms and resists compromise that perpetuates structural problems |
| Goalpost stability | Highly stable: has consistently called for descheduling, racial justice, and dismantling DEA scheduling authority for decades |
| Zero-sum behavior | Low: will ally with moderates on incremental steps while maintaining pressure for structural change |

**Justification:** Progressives are the most consistent advocates for comprehensive scheduling reform. Their positions follow directly from principles of racial justice, public health over criminalization, and skepticism of law enforcement authority over medical and scientific decisions. The high score reflects genuine principle consistency, not merely ideological rigidity -- progressives have supported incremental reforms (First Step Act, rescheduling) while maintaining long-term structural goals.

**Evidence for assessment:**

- Congressional Progressive Caucus has consistently supported cannabis descheduling and broader scheduling reform
- Progressive organizations (DPA, ACLU, NORML) have maintained consistent positions for decades
- Progressive leaders introduced the MORE Act and Cannabis Administration and Opportunity Act

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 10/10 | Fully agrees with analysis; would place even greater emphasis on racial dimensions and pharmaceutical industry role |
| Root Cause Agreement | 10/10 | Fully agrees with structural analysis of DEA authority, political economy, and racial dynamics |

**Source references:**

- Drug Policy Alliance. "Drug Scheduling Reform: A Racial Justice Imperative." 2023.
- ACLU. "A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform." 2020.

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Independent Drug Classification Commission | 9/10 | Strongly supports; views as essential structural reform | Would ensure commission explicitly addresses racial equity |
| Cannabis rescheduling to Schedule III | 5/10 | Supports as interim step only; insufficient alone | Rescheduling maintains federal criminal framework; does not deliver racial justice |
| Eliminate Schedule I research barriers | 9/10 | Strongly supports | No significant objections |
| Cannabis descheduling | 10/10 | Core priority; must include equity and expungement provisions | Would pair with comprehensive reparative justice framework |
| Evidence-based penalty reform | 9/10 | Strongly supports; would go further toward full decriminalization | Would eliminate criminal penalties for all personal use, not just adjust proportionality |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| Evidence-Based Drug Classification Act | 9/10 | Strong support; essential structural reform | Would add equity mandate to Commission charter |
| SAFE Research Act | 9/10 | Strong support | No major objections |
| MORE Act (descheduling) | 10/10 | Top legislative priority | Would strengthen social equity and expungement provisions |

#### Alternative Proposals

Progressives would add: (1) comprehensive reparative justice for communities targeted by War on Drugs, including reinvestment of drug enforcement savings; (2) decriminalization of personal possession of all drugs (not just cannabis); (3) pharmaceutical industry accountability provisions linking scheduling reform to corporate accountability for the opioid crisis; (4) community reinvestment funds from cannabis tax revenue directed to communities most harmed by prohibition.

#### Coalition Potential

- **Natural allies:** Liberal, Democratic Socialist (shared structural reform and equity priorities)
- **Potential bridges:** Libertarian (shared opposition to drug prohibition, though different reasoning); Populist (shared anti-corporate sentiment)
- **Unlikely partners:** Conservative, Religious Right (fundamental disagreement on decriminalization and moral framing)

---

### Libertarian Perspective

#### Engagement Consistency Assessment

**Score: 5/5 - Highly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Positions on scheduling reform flow directly and consistently from individual liberty principles |
| Principle consistency | Very high: applies anti-prohibition, anti-regulation principles uniformly across all substances; does not carve out exceptions based on political convenience |
| Goalpost stability | Highly stable: has advocated drug legalization for decades with little variation |
| Zero-sum behavior | Low: willing to support incremental reforms that move toward liberty even if incomplete |

**Justification:** Libertarians are the most principled opponents of drug prohibition as a concept. Their support for scheduling reform is not politically motivated but flows directly from core beliefs about individual sovereignty over one's body and skepticism of government authority. The high consistency score reflects decades of unwavering advocacy for drug legalization through Cato Institute, Reason Foundation, and Libertarian Party platforms.

**Evidence for assessment:**

- Cato Institute has published drug legalization analyses since the 1980s
- Libertarian Party platform has called for ending drug prohibition since its founding (1972)
- Sen. Rand Paul (libertarian-leaning Republican) has consistently co-sponsored cannabis and psychedelic reform legislation

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 8/10 | Agrees that scheduling system is dysfunctional and scientifically indefensible; less focused on racial dimensions, more on individual liberty |
| Root Cause Agreement | 7/10 | Agrees that government authority over drug classification is the core problem; attributes dysfunction to government overreach rather than specific institutional design flaws |

**Source references:**

- Cato Institute. "The Case Against Drug Prohibition." Policy Analysis Series.
- Reason Foundation. Drug policy coverage. <https://reason.org/>

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Independent Drug Classification Commission | 5/10 | Skeptical: replacing one government body with another does not address root problem of government drug classification | Prefers reducing government authority, not reorganizing it |
| Cannabis rescheduling to Schedule III | 4/10 | Supports as marginal improvement; far short of what is needed | Rescheduling keeps cannabis under government control |
| Eliminate Schedule I research barriers | 8/10 | Supports removing government barriers to research | Research should not require government permission at all |
| Cannabis descheduling | 8/10 | Supports but would go further -- deschedule all or most substances | Descheduling cannabis alone is arbitrary; why not mushrooms, MDMA, all drugs? |
| Evidence-based penalty reform | 7/10 | Supports reducing penalties; would prefer eliminating all drug crimes except fraud/contamination | Government should not criminalize voluntary adult consumption |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| Evidence-Based Drug Classification Act | 5/10 | Better than current system but creates new bureaucracy | Would prefer eliminating scheduling authority rather than transferring it |
| SAFE Research Act | 7/10 | Supports; research should not require government permission but this is an improvement | Incremental; does not address fundamental overreach |
| MORE Act (descheduling) | 7/10 | Supports descheduling; concerned about new regulatory framework replacing old prohibition | Prefers minimal regulation, not new federal regulatory agency |

#### Alternative Proposals

Libertarians would prefer: (1) complete descheduling of all drugs with adults free to make their own consumption decisions; (2) replace scheduling with a consumer information system (like nutrition labels) rather than prohibition; (3) criminal penalties only for fraud, contamination, or distribution to minors; (4) no new federal regulatory agency for cannabis -- let states and markets regulate.

#### Coalition Potential

- **Natural allies:** None perfectly aligned, but overlap with Progressive (shared anti-prohibition goals) and Constitutionalist (shared anti-federal-authority concerns)
- **Potential bridges:** Conservative (shared federalism concerns); Liberal (shared support for rescheduling and research)
- **Unlikely partners:** Religious Right (disagrees on moral legitimacy of drug use); Populist (disagrees on role of government authority)

---

### Constitutionalist Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuinely motivated by constitutional structure and enumerated powers analysis; positions generally follow from federalism principles |
| Principle consistency | High for structural arguments; some tension when federalism principles support outcomes that conflict with social conservatism (e.g., state cannabis legalization) |
| Goalpost stability | Generally stable on structural/constitutional questions; some flexibility on specific substances |
| Zero-sum behavior | Low: tends to evaluate scheduling questions through constitutional framework rather than political dynamics |

**Justification:** Constitutionalists bring a distinctive lens to scheduling reform: the question is not primarily whether cannabis should be legal but whether the federal government has the authority (and wisdom) to override state decisions. This is a principled position that occasionally creates tension with social conservative allies. The 4/5 score reflects genuine consistency on structural questions with minor inconsistency when federalism principles support drug reform outcomes some constitutionalists are uncomfortable with.

**Evidence for assessment:**

- Federalist Society has published analyses questioning federal marijuana prohibition authority
- Some originalist scholars argue the CSA's breadth exceeds enumerated powers (pre-*Raich*)
- Constitutionalist legislators have supported STATES Act approach

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 6/10 | Agrees that federal scheduling creates federal-state conflict; questions whether *Raich* was correctly decided; less interested in pharmacological arguments |
| Root Cause Agreement | 5/10 | Agrees that concentrated federal authority is problematic but frames issue as structural overreach rather than institutional capture; less interested in racial dimensions |

**Source references:**

- Barnett, Randy. Brief of Amici Curiae in *Gonzales v. Raich* (arguing against federal marijuana authority under Commerce Clause)
- Federalist Society. "Drug Policy and Federalism." Regulatory Transparency Project, 2022.

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Independent Drug Classification Commission | 4/10 | Skeptical of creating new federal body; prefers reducing federal authority | New commission still represents federal power over states |
| Cannabis rescheduling to Schedule III | 5/10 | Accepts as practical measure; prefers Congressional action over administrative | Questions whether scheduling authority delegation is constitutional |
| Eliminate Schedule I research barriers | 6/10 | Supports reducing federal barriers; prefers state-led research |  Would prefer states control their own research access |
| Cannabis descheduling | 7/10 | Supports on federalism grounds: return authority to states | Most constitutionally sound approach; eliminates federal overreach |
| Evidence-based penalty reform | 5/10 | Supports reducing federal penalties; prefers state-level penalty decisions | Federal criminal law should be narrower; states should set their own penalty structures |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| Evidence-Based Drug Classification Act | 4/10 | Concerned about non-delegation and new federal authority | Prefers reducing federal scheduling role, not restructuring it |
| SAFE Research Act | 6/10 | Moderately supportive; reduces federal barriers | Should pair with expanded state authority |
| MORE Act (descheduling) | 6/10 | Supports descheduling component; skeptical of new federal regulatory framework | Descheduling good; new federal agency less desirable |

#### Alternative Proposals

Constitutionalists would prefer: (1) STATES Act approach -- protect state cannabis programs from federal enforcement without rescheduling; (2) descheduling cannabis entirely and returning regulatory authority to states; (3) narrowing Commerce Clause interpretation to limit federal scheduling authority over intrastate drug activity; (4) sunset the CSA's broadest provisions and require re-authorization with enumerated powers justification.

#### Coalition Potential

- **Natural allies:** Libertarian (shared anti-federal-authority concerns)
- **Potential bridges:** Conservative (shared respect for traditional institutions, though different conclusions on federal authority); Populist (shared skepticism of federal elite decision-making)
- **Unlikely partners:** Progressive, Democratic Socialist (different views on federal government role; progressives want stronger federal equity mandates)

---

### Populist Perspective

#### Engagement Consistency Assessment

**Score: 2/5 - Low Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Positions are influenced by cultural signaling and opposition dynamics as much as by policy substance; populist drug policy varies dramatically based on which elites are being opposed |
| Principle consistency | Low: simultaneously anti-elite and pro-law enforcement; anti-pharmaceutical industry but sometimes anti-cannabis reform; inconsistent application of anti-establishment principles |
| Goalpost stability | Unstable: positions shift based on which political leader or faction is championing reform |
| Zero-sum behavior | High: tends to frame scheduling reform as either supporting or opposing political enemies rather than evaluating policy merits |

**Justification:** Populism's drug scheduling positions are the most internally contradictory of all perspectives. Populists are fiercely anti-pharmaceutical industry (supporting accountability for the opioid crisis), anti-elite (opposing "Washington bureaucrats" at the DEA), and pro-community protection (supporting tough enforcement against drug trafficking). These impulses pull in different directions on scheduling reform. The low consistency score reflects the genuine unpredictability of populist positions, which depend heavily on framing and political context.

**Evidence for assessment:**

- Trump administration supported First Step Act sentencing reform but opposed cannabis legalization
- Populist leaders have simultaneously attacked pharmaceutical companies and opposed drug decriminalization
- Congressional populists have been split on cannabis reform, with some supporting states' rights approach and others opposing any reform

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 5/10 | Agrees that pharmaceutical industry is corrupt and DEA is bureaucratic; disagrees with framing that minimizes drug dangers or emphasizes racial justice over community safety |
| Root Cause Agreement | 4/10 | Strongly agrees on pharmaceutical industry critique; disagrees on law enforcement critique; ambivalent on racial analysis |

**Source references:**

- Various populist commentators and media outlets (positions vary significantly by source)
- Trump administration drug policy positions (mixed: First Step Act + opposition to legalization)

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Independent Drug Classification Commission | 3/10 | Suspicious of new "expert" body making decisions for communities | Elitist institution; unaccountable to regular people |
| Cannabis rescheduling to Schedule III | 5/10 | Mixed: some support for veterans and medical patients; resistance to "Big Cannabis" | Worried about commercialization; supportive of medical access |
| Eliminate Schedule I research barriers | 6/10 | Generally supportive of letting scientists do their work | Less interested in research process; more interested in outcomes |
| Cannabis descheduling | 4/10 | Split: supports states' rights but opposes "Big Cannabis" corporatization | Concerned about corporate capture of legal cannabis market |
| Evidence-based penalty reform | 5/10 | Supports reduced penalties for users; wants harsh penalties for traffickers and cartels | Distinguishes between "victims" (users) and "villains" (cartels, pharma) |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| Evidence-Based Drug Classification Act | 3/10 | Suspicious of expert commission; wants popular accountability | Commission would be captured by pharma lobbyists |
| SAFE Research Act | 5/10 | Moderately supportive | Not a high priority issue |
| MORE Act (descheduling) | 4/10 | Concerns about Big Cannabis; supportive of expungement for regular people | Would support if anti-corporate provisions were stronger |

#### Alternative Proposals

Populists would prefer: (1) harsh penalties for pharmaceutical executives who promote addictive drugs while reducing penalties for users; (2) cannabis reform that benefits small growers and local businesses, not corporate chains; (3) prioritizing fentanyl enforcement over cannabis reform; (4) direct popular vote or referendum on scheduling changes rather than expert commission decisions.

#### Coalition Potential

- **Natural allies:** No natural allies (populism cuts across traditional lines)
- **Potential bridges:** Conservative (shared law enforcement support); Progressive (shared anti-corporate sentiment); Constitutionalist (shared anti-federal-elite sentiment)
- **Unlikely partners:** Libertarian (disagrees on need for government enforcement); Centrist (populists distrust centrist technocratic approaches)

---

### Centrist Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuinely motivated by evidence-based, pragmatic policy; positions align with stated principles of incremental, data-driven reform |
| Principle consistency | High: consistently applies evidence-based framework; may prioritize political feasibility over optimal policy |
| Goalpost stability | Stable: positions evolve incrementally as evidence accumulates; predictable negotiating partner |
| Zero-sum behavior | Very low: actively seeks compromise and bipartisan solutions |

**Justification:** Centrists are natural allies for scheduling reform because the reform case is fundamentally evidence-based. The analysis presented in this project aligns closely with centrist values: follow the science, reduce unnecessary government intrusion, fix what's clearly broken, and do so incrementally. The 4/5 score reflects occasional over-prioritization of political feasibility at the expense of needed structural reform.

**Evidence for assessment:**

- Bipartisan Policy Center has published analyses supporting cannabis rescheduling
- Centrist senators (e.g., Jon Tester, previous; Mark Kelly) have supported cannabis banking and rescheduling
- No Labels, Third Way, and similar centrist organizations support evidence-based drug policy reform

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 8/10 | Largely agrees with evidence-based assessment of scheduling system's dysfunctions; may downplay structural/racial analysis in favor of technocratic framing |
| Root Cause Agreement | 7/10 | Agrees on institutional design problems and research barriers; less comfortable with political economy critique that assigns blame |

**Source references:**

- Bipartisan Policy Center. "Bipartisan Drug Policy Recommendations." 2023.
- Third Way. "Cannabis Policy: A Pragmatic Approach." 2023.

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Independent Drug Classification Commission | 7/10 | Supports concept of expert scientific body; wants to ensure bipartisan composition | Concerned about political backlash if commission makes unpopular decisions |
| Cannabis rescheduling to Schedule III | 9/10 | Strongly supports as evidence-based, achievable reform | This is the centrist sweet spot: follows science, achievable, not radical |
| Eliminate Schedule I research barriers | 9/10 | Strongly supports; this is consensus policy with bipartisan appeal | No significant concerns |
| Cannabis descheduling | 5/10 | Open to it as long-term goal; prefers rescheduling as practical near-term step | Concerned about moving too fast; prefers incremental approach |
| Evidence-based penalty reform | 7/10 | Supports proportional penalties; cautious about eliminating all mandatory minimums | Wants to maintain some deterrence tools; supports Sentencing Commission authority |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| Evidence-Based Drug Classification Act | 7/10 | Supports expert commission concept; wants bipartisan design features | Would strengthen bipartisan provisions and transition safeguards |
| SAFE Research Act | 9/10 | Strongly supports; ideal centrist legislation (evidence-based, bipartisan, targeted) | No major concerns |
| MORE Act (descheduling) | 5/10 | Supports some provisions; prefers more incremental approach | Too ambitious for near-term political environment |

#### Alternative Proposals

Centrists would emphasize: (1) completing cannabis rescheduling to Schedule III through existing administrative process as first priority; (2) bipartisan SAFE Research Act as legislative priority with broad appeal; (3) SAFE Banking Act for cannabis businesses as practical bipartisan measure; (4) incrementally building toward broader reform as evidence accumulates and political support grows.

#### Coalition Potential

- **Natural allies:** Liberal (shared evidence-based, incremental approach)
- **Potential bridges:** Conservative (can negotiate incremental reforms); Libertarian (common ground on research access and rescheduling)
- **Unlikely partners:** None are impossible; centrists seek to build bridges with all perspectives

---

### Religious Right Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine moral concern about drug use and family impact; but positions sometimes shift when opioid crisis affects their communities directly |
| Principle consistency | Mixed: moral opposition to drug normalization is consistent, but treatment support for opioids while opposing cannabis reform reveals substance-specific inconsistency |
| Goalpost stability | Moderate: has shifted from blanket prohibition advocacy to accepting some medical cannabis and treatment-oriented approaches |
| Zero-sum behavior | Moderate: tends to view scheduling reform as part of broader cultural decline rather than evaluating specific proposals on merits |

**Justification:** The Religious Right brings genuine moral concern to drug scheduling debates, grounded in concern for families and communities affected by addiction. The mixed consistency score reflects the tension between moral opposition to drug normalization and the reality that their communities have been devastated by the opioid crisis (driven by legal, scheduled drugs). This tension has created meaningful evolution: many Religious Right organizations now support treatment-based approaches, faith-based recovery programs, and some medical cannabis access.

**Evidence for assessment:**

- National Association of Evangelicals has supported drug treatment and criminal justice reform
- Some evangelical leaders have endorsed medical cannabis for pain management
- Family Research Council continues to oppose cannabis legalization while supporting opioid treatment

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 4/10 | Accepts some scheduling system problems (especially opioid-related) but disagrees with analysis's implicit endorsement of cannabis and psychedelic therapeutic potential; frames drug use as moral rather than medical issue |
| Root Cause Agreement | 3/10 | Attributes drug problems to moral decline, family breakdown, and insufficient spiritual resources rather than institutional design or racial dynamics |

**Source references:**

- Family Research Council. Positions on drug policy and scheduling.
- National Association of Evangelicals. "Resolution on Criminal Justice Reform." 2015.

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Independent Drug Classification Commission | 3/10 | Concerned that secular scientific body would ignore moral dimensions of drug use | Fears commission would liberalize scheduling based only on physical harm, ignoring spiritual and family harm |
| Cannabis rescheduling to Schedule III | 4/10 | Cautiously supportive for genuine medical use; opposes if it leads to recreational access | Gateway to normalization; undermines moral message about drug abstinence |
| Eliminate Schedule I research barriers | 6/10 | Supports research to understand drugs better; wants results to inform careful policy | Supportive if research serves treatment and prevention, not normalization |
| Cannabis descheduling | 2/10 | Strongly opposes; views as surrender in cultural battle against drug use | Legalizing cannabis is morally wrong; harms families and children |
| Evidence-based penalty reform | 4/10 | Supports treatment alternatives for addicts (faith-based recovery); wants strong penalties for dealers | Distinguishes between victims of addiction (who need redemption) and traffickers (who deserve punishment) |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| Evidence-Based Drug Classification Act | 3/10 | Opposes secular commission making moral decisions | Would want moral/community impact assessment included |
| SAFE Research Act | 5/10 | Cautiously supportive of research access | Wants research focused on harm prevention, not therapeutic use justification |
| MORE Act (descheduling) | 1/10 | Strongly opposes | Normalizes drug use; harms families; undermines moral fabric |

#### Alternative Proposals

The Religious Right would prefer: (1) expanded faith-based recovery programs funded by federal grants; (2) maintaining cannabis Schedule I status while funding pharmaceutical development of specific cannabinoid medications; (3) stronger enforcement against drug trafficking, especially fentanyl; (4) school-based prevention programs emphasizing abstinence and moral values; (5) compassionate treatment alternatives to incarceration for people with addiction, especially through faith-based organizations.

#### Coalition Potential

- **Natural allies:** Conservative (shared concern about drug normalization and family values)
- **Potential bridges:** Populist (shared concern about communities harmed by drugs); Centrist (possible common ground on treatment and opioid response)
- **Unlikely partners:** Progressive, Libertarian, Democratic Socialist (fundamental disagreement on moral framing and government's role in regulating personal behavior)

---

### Democratic Socialist Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Positions flow consistently from anti-corporate, pro-worker, public-health-centered principles |
| Principle consistency | High: applies class analysis and corporate accountability lens consistently to drug scheduling |
| Goalpost stability | Stable: has consistently supported descheduling, decriminalization, and pharmaceutical industry accountability |
| Zero-sum behavior | Low: willing to support incremental reforms while maintaining structural critique |

**Justification:** Democratic socialists bring a distinctive class-based analysis to scheduling reform, emphasizing pharmaceutical industry profits, corporate accountability, and the disproportionate burden of drug enforcement on working-class communities. Their positions are internally consistent and predictable. The slight reduction from a 5 reflects occasional tension between supporting government regulation (for pharmaceutical industry) and opposing government regulation (for personal drug use).

**Evidence for assessment:**

- DSA platform supports drug decriminalization and scheduling reform
- Sen. Bernie Sanders has supported cannabis legalization and scheduling reform
- Democratic socialist representatives have co-sponsored MORE Act and cannabis reform legislation

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | Largely agrees; would further emphasize pharmaceutical industry profits and class dimensions of enforcement |
| Root Cause Agreement | 9/10 | Strongly agrees with political economy analysis; would further emphasize corporate capture and profit motives |

**Source references:**

- Democratic Socialists of America. Platform positions on drug policy.
- Sanders, Bernie. Campaign positions on cannabis legalization and drug policy reform.

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| Independent Drug Classification Commission | 7/10 | Supports in principle; concerned about corporate capture | Must include anti-corporate-capture provisions; no pharma industry representatives |
| Cannabis rescheduling to Schedule III | 5/10 | Supports as interim step; insufficient for structural reform | Does not address corporate domination of cannabis industry or worker exploitation |
| Eliminate Schedule I research barriers | 8/10 | Supports; research should be publicly funded and publicly accessible | Concerned that corporate-funded research could bias results toward patentable products |
| Cannabis descheduling | 9/10 | Strongly supports; must include worker protections and anti-monopoly provisions | Cannabis industry must be structured to benefit communities and workers, not just investors |
| Evidence-based penalty reform | 9/10 | Strongly supports; would go further toward full decriminalization | All personal drug use should be decriminalized; penalties only for corporate malfeasance |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| Evidence-Based Drug Classification Act | 7/10 | Supports commission concept with anti-corporate-capture provisions | Would add pharmaceutical industry conflict-of-interest restrictions |
| SAFE Research Act | 8/10 | Supports; would add public funding requirements for research | Research should serve public interest, not pharma profits |
| MORE Act (descheduling) | 8/10 | Supports; would strengthen equity and worker protection provisions | Must prevent corporate cannabis monopolies |

#### Alternative Proposals

Democratic socialists would add: (1) public option for cannabis production and distribution (state-owned dispensaries alongside private market); (2) pharmaceutical industry windfall profits tax directed toward addiction treatment; (3) worker ownership incentives for cannabis businesses; (4) publicly funded drug research with publicly accessible results (no patent monopolies on research from public institutions); (5) community reinvestment requirements for cannabis tax revenue.

#### Coalition Potential

- **Natural allies:** Progressive (shared structural reform priorities and equity commitments)
- **Potential bridges:** Liberal (common ground on reform goals; disagree on corporate regulation approach); Populist (shared anti-corporate sentiment, though different solutions)
- **Unlikely partners:** Conservative, Libertarian (fundamental disagreements on government role in markets and corporate regulation)

---

## Summary Tables

### Master Comparison

| Perspective | Consistency | Current State | Root Causes | Solutions Avg | Legislation Avg |
|-------------|-------------|---------------|-------------|---------------|-----------------|
| Conservative | 3/5 | 5/10 | 4/10 | 4.2/10 | 3.7/10 |
| Liberal | 4/5 | 9/10 | 8/10 | 8.4/10 | 8.7/10 |
| Progressive | 5/5 | 10/10 | 10/10 | 8.4/10 | 9.3/10 |
| Libertarian | 5/5 | 8/10 | 7/10 | 6.4/10 | 6.3/10 |
| Constitutionalist | 4/5 | 6/10 | 5/10 | 5.4/10 | 5.3/10 |
| Populist | 2/5 | 5/10 | 4/10 | 4.6/10 | 4.0/10 |
| Centrist | 4/5 | 8/10 | 7/10 | 7.4/10 | 7.0/10 |
| Religious Right | 3/5 | 4/10 | 3/10 | 3.8/10 | 3.0/10 |
| Democratic Socialist | 4/5 | 9/10 | 9/10 | 7.6/10 | 7.7/10 |

### Solution Support Matrix

| Solution | Con | Lib | Prog | Libt | Const | Pop | Cent | RelR | DemSoc |
|----------|-----|-----|------|------|-------|-----|------|------|--------|
| Independent Drug Classification Commission | 3 | 8 | 9 | 5 | 4 | 3 | 7 | 3 | 7 |
| Cannabis rescheduling to Schedule III | 5 | 7 | 5 | 4 | 5 | 5 | 9 | 4 | 5 |
| Eliminate Schedule I research barriers | 7 | 9 | 9 | 8 | 6 | 6 | 9 | 6 | 8 |
| Cannabis descheduling | 2 | 9 | 10 | 8 | 7 | 4 | 5 | 2 | 9 |
| Evidence-based penalty reform | 4 | 8 | 9 | 7 | 5 | 5 | 7 | 4 | 9 |

### Legislation Support Matrix

| Bill | Con | Lib | Prog | Libt | Const | Pop | Cent | RelR | DemSoc |
|------|-----|-----|------|------|-------|-----|------|------|--------|
| Evidence-Based Drug Classification Act | 3 | 8 | 9 | 5 | 4 | 3 | 7 | 3 | 7 |
| SAFE Research Act | 6 | 9 | 9 | 7 | 6 | 5 | 9 | 5 | 8 |
| MORE Act (descheduling) | 2 | 9 | 10 | 7 | 6 | 4 | 5 | 1 | 8 |

### Engagement Consistency Distribution

| Level | Count | Perspectives |
|-------|-------|--------------|
| 5 - Highly Consistent | 2 | Progressive, Libertarian |
| 4 - Mostly Consistent | 4 | Liberal, Constitutionalist, Centrist, Democratic Socialist |
| 3 - Mixed Consistency | 2 | Conservative, Religious Right |
| 2 - Low Consistency | 1 | Populist |
| 1 - Unpredictable | 0 | None |

**High Consistency Majority:** 6/9 perspectives rated 4 or above

### Common Ground Synthesis

This matrix identifies which reforms have potential cross-ideological support and which face structural opposition.

| Reform Category | Broad Support (5+) | Narrow Support (3-4) | Structural Opposition |
|-----------------|-------------------|---------------------|----------------------|
| Eliminate Schedule I research barriers | Conservative, Liberal, Progressive, Libertarian, Constitutionalist, Populist, Centrist, Religious Right, Democratic Socialist (9/9) | None | None |
| Cannabis rescheduling to Schedule III | Liberal, Progressive, Centrist, Conservative, Populist, Constitutionalist (6/9) | Libertarian, Religious Right, Democratic Socialist (3/9 -- support but view as insufficient) | None with structural opposition |
| Evidence-based penalty reform | Liberal, Progressive, Libertarian, Centrist, Populist, Democratic Socialist (6/9) | Conservative, Constitutionalist, Religious Right (3/9) | None |
| Independent Drug Classification Commission | Liberal, Progressive, Centrist, Democratic Socialist (4/9) | Libertarian, Constitutionalist (2/9) | Conservative, Populist, Religious Right (3/9) |
| Cannabis descheduling | Liberal, Progressive, Libertarian, Constitutionalist, Democratic Socialist (5/9) | Centrist, Populist (2/9) | Conservative, Religious Right (2/9) |

**Key insight:** Eliminating Schedule I research barriers has universal support across all nine perspectives -- this is the single most achievable reform. Cannabis rescheduling to Schedule III has broad support (6/9) with three additional perspectives viewing it as insufficient rather than opposing it. The Independent Drug Classification Commission faces structural opposition from three perspectives, making it a medium-term rather than near-term legislative priority.

---

## Compromise Proposals

### Compromise 1: *Bipartisan Research Access and Cannabis Rescheduling Package*

**Bridges:** Conservative + Liberal + Centrist + Libertarian + Constitutionalist + Populist

**Core Agreement:** All perspectives agree that Schedule I research barriers impede scientific progress. Most agree cannabis scheduling is indefensible. A package combining research access reform with cannabis rescheduling addresses the broadest possible coalition.

**Policy Description:**

Combine the SAFE Research Act (90-day research licensing, multiple suppliers, breakthrough therapy access) with administrative cannabis rescheduling to Schedule III. Include provisions protecting state medical cannabis programs from federal interference. Add enhanced fentanyl enforcement provisions to address populist and conservative concerns. Pair with veterans' cannabis access provisions to strengthen bipartisan appeal.

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Conservative | Maintains DEA enforcement role; strengthens fentanyl response; supports veterans; incremental approach |
| Liberal | Advances research access; moves cannabis toward Schedule III; protects state programs |
| Centrist | Evidence-based, achievable, bipartisan; follows HHS scientific recommendation |
| Libertarian | Reduces government barriers; moves toward rescheduling; research freedom |
| Constitutionalist | Respects state programs; reduces federal overreach on cannabis |
| Populist | Supports veterans and patients; tough on fentanyl; protects communities |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Conservative | Accepting cannabis rescheduling rather than maintaining status quo |
| Liberal | Accepting rescheduling rather than descheduling; no expungement in this package |
| Centrist | Moving on cannabis rescheduling may be faster than preferred political timeline |
| Libertarian | Accepting government-managed rescheduling rather than full descheduling |
| Constitutionalist | Accepting federal rescheduling rather than pure states' rights approach |
| Populist | Accepting some scheduling reform despite cultural concerns |

**Viability Assessment:**

- **Coalition Size:** 6/9 perspectives
- **High Consistency Ratio:** 4/6 coalition members rated 4+ consistency
- **Durability:** High -- research access has universal support; cannabis rescheduling follows HHS science
- **Implementation Path:** SAFE Research Act as standalone legislation + support for DEA administrative cannabis rescheduling process

---

### Compromise 2: *Veterans and Patients Scheduling Access Act*

**Bridges:** Conservative + Liberal + Progressive + Centrist + Populist + Religious Right

**Core Agreement:** All perspectives support improving access to therapeutic substances for veterans and seriously ill patients, even if they disagree on broader scheduling reform.

**Policy Description:**

Create a targeted therapeutic access pathway allowing VA physicians to recommend medical cannabis in states where it is legal, and expanding access to FDA-approved clinical trials for psilocybin-assisted PTSD treatment. Include faith-based recovery program funding to engage the Religious Right. Establish compassionate use provisions for terminally ill patients seeking Schedule I substances. Fund veteran-specific research on cannabis and psychedelic therapies.

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Conservative | Supports veterans; targeted rather than broad reform; medical focus |
| Liberal | Expands therapeutic access; reduces barriers for patients |
| Progressive | Helps most vulnerable populations; builds toward broader reform |
| Centrist | Evidence-based; targeted; high public support |
| Populist | Veterans and patients first; protects communities |
| Religious Right | Faith-based recovery included; compassionate focus; medical not recreational |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Conservative | Accepting some cannabis access expansion, even if limited to VA/medical |
| Liberal | Accepting narrow scope rather than comprehensive reform |
| Progressive | Accepting targeted approach rather than structural reform |
| Religious Right | Accepting any cannabis-related access expansion |
| Populist | Accepting expert-guided therapeutic decisions |

**Viability Assessment:**

- **Coalition Size:** 6/9 perspectives
- **High Consistency Ratio:** 4/6 coalition members rated 4+ consistency
- **Durability:** High -- veteran and patient access is difficult to oppose politically
- **Implementation Path:** Bipartisan legislation through Senate Veterans' Affairs and HELP Committees; executive action allowing VA cannabis recommendations

---

### Compromise 3: *Science-Based Scheduling and Fentanyl Enforcement Act*

**Bridges:** Conservative + Liberal + Progressive + Centrist + Populist + Democratic Socialist

**Core Agreement:** Pair structural scheduling reform (mandatory scientific review) with enhanced enforcement against fentanyl trafficking, creating a package that balances reform with enforcement.

**Policy Description:**

Establish mandatory 10-year scientific review of all scheduled substances (addressing reform advocates) while permanently scheduling all fentanyl analogs and strengthening fentanyl trafficking penalties (addressing enforcement advocates). Include funding for treatment and harm reduction alongside enforcement. Create a small scientific advisory panel within HHS (short of a full independent commission) to conduct reviews with public transparency requirements.

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Conservative | Strengthens fentanyl enforcement; maintains DEA role; incremental scientific review |
| Liberal | Establishes mandatory review principle; addresses fentanyl crisis; treatment funding |
| Progressive | Creates review mechanism that will eventually correct scheduling errors; harm reduction funding |
| Centrist | Balanced approach; evidence-based review with enforcement; bipartisan |
| Populist | Tough on fentanyl; protects communities; holds system accountable |
| Democratic Socialist | Creates accountability mechanism; treatment funding; anti-corporate provisions in fentanyl enforcement |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Conservative | Accepting mandatory review mechanism that may lead to rescheduling |
| Liberal | Accepting enhanced enforcement provisions alongside reform |
| Progressive | Accepting advisory panel rather than binding independent commission |
| Centrist | Accepting enforcement provisions that may be more aggressive than preferred |
| Populist | Accepting expert review process |
| Democratic Socialist | Accepting enforcement component |

**Viability Assessment:**

- **Coalition Size:** 6/9 perspectives
- **High Consistency Ratio:** 4/6 coalition members rated 4+ consistency
- **Durability:** Moderate-High -- fentanyl enforcement provides political cover for scheduling review mechanism
- **Implementation Path:** Omnibus legislation combining scheduling review with fentanyl enforcement; attach to appropriations or defense authorization

---

## Strategic Implications

### Most Viable Coalition

The Liberal-Centrist-Libertarian-Progressive coalition is the most natural alignment for comprehensive scheduling reform. These four perspectives agree on the core diagnosis (scheduling system is scientifically indefensible) and differ mainly on the scope and pace of reform. Adding Conservative support for targeted measures (research access, veterans' access, cannabis rescheduling to Schedule III) creates a working supermajority for incremental reform.

### Key Obstacles

1. **Conservative ambivalence**: Conservatives are the swing vote on scheduling reform. Their federalist principles support reform, but cultural opposition to drug normalization and law enforcement constituency pressure create resistance. Research access and veterans' access are the entry points most likely to secure conservative support.
2. **Religious Right opposition**: The Religious Right's moral framing of drug use creates the most durable opposition to comprehensive reform. Engagement strategies should focus on treatment and compassion rather than liberty or science.
3. **Populist unpredictability**: With only 2/5 consistency, populist positions on scheduling reform are highly sensitive to political context and framing. Anti-pharmaceutical and pro-veteran framing can engage populist support, but positions may shift rapidly.

### Low Consistency Partners

- **Populist (2/5)**: Address through anti-corporate framing (pharmaceutical industry accountability) and community protection messaging (fentanyl enforcement). Avoid elite-technocratic framing. Expect positions to require ongoing re-engagement.
- **Conservative (3/5)**: Address through federalism, veterans' access, and research framing. Build relationships with conservative champions (e.g., libertarian-leaning Republicans). Accept incremental progress.
- **Religious Right (3/5)**: Engage through faith-based recovery partnerships and compassionate treatment messaging. Do not expect support for descheduling or recreational access.

### Recommended Approach

1. **Immediate priority**: SAFE Research Act as standalone bipartisan legislation (9/9 perspective support for research access) paired with support for administrative cannabis rescheduling to Schedule III (6/9 support)
2. **Near-term**: Veterans and Patients Scheduling Access Act to build bipartisan coalition and demonstrate that scheduling reform improves health outcomes
3. **Medium-term**: Science-Based Scheduling and Fentanyl Enforcement Act combining mandatory review with enforcement to create a durable institutional reform mechanism
4. **Long-term**: Evidence-Based Drug Classification Act establishing independent commission, building on demonstrated success of mandatory review process and accumulated political capital from earlier reforms

---

## Document Navigation

- Previous: [Legislation](11-legislation.md)
